Post-acute Myocarditis Persistent Inflammation Score (MRI + Biomarkers) Calculator
- Post-acute Myocarditis Persistent Inflammation Score (MRI + Biomarkers): Explanation and Clinical Context
This calculator provides a pragmatic, literature-informed composite score to estimate the likelihood of persistent myocardial inflammation after an acute myocarditis episode using follow-up cardiovascular magnetic resonance (CMR) features and blood biomarkers. It weights factors consistently linked with adverse outcomes or ongoing inflammation at follow-up: persistence or progression of late gadolinium enhancement (LGE), septal LGE, larger LGE burden, edema (T2), diffuse injury (native T1/ECV), left ventricular systolic dysfunction (LVEF) and impaired deformation (GLS), together with persistent myocardial injury (hs-troponin), neurohormonal stress (NT-proBNP), and systemic inflammation (CRP). Cut-points and weights are aligned with signals reported across contemporary studies and consensus documents; notably, follow-up CMR around 3 months is commonly recommended to detect residual disease activity and high-risk LGE patterns or extent.
How to interpret:
Low risk (0–2) suggests a low likelihood of ongoing active inflammation; routine clinical follow-up is generally appropriate. Intermediate risk (3–4) indicates possible persistent inflammation; consider closer monitoring and repeat CMR if symptoms, biomarkers, or ECG change. High risk (≥5) reflects a higher probability of persistent inflammation and of adverse events; consider intensifying follow-up, risk-factor control, and therapy in line with expert consensus, and individualize decisions with a cardiomyopathy/myocarditis team. This score is not a substitute for clinical judgment, endomyocardial biopsy when indicated, or guideline-directed management. It is intended to standardize phenotyping at follow-up and to complement existing guidance.
Notes on evidence and derivation:
• Persistence/progression of LGE at ~6-month CMR, septal LGE, reduced LVEF at admission/follow-up, impaired GLS, and prolonged troponin elevation were all associated with adverse events in a prospective cohort proposing a multiparametric prognostic score (Di Lisi et al., 2024).
• Reviews and consensus statements emphasize that CMR integrates edema (T2), necrosis/fibrosis (LGE), and diffuse injury (native T1/ECV) and should be repeated at ≈3 months to detect residual inflammation and high-risk LGE extent/patterns; enzymes alone may normalize despite ongoing LGE.
• Biomarker dynamics (hs-cTn, NT-proBNP) and systemic inflammatory markers (e.g., CRP) can add prognostic information but do not replace imaging; persistent abnormality beyond the acute phase supports ongoing disease activity.
• Because no single universally validated “post-acute persistent inflammation” score is yet established, this calculator operationalizes published risk signals into a transparent point system to aid consistent reporting and shared decision-making. Where available, users should also consult original risk models and apply lab-specific reference limits.
References:
Di Lisi D, et al. A new risk assessment tool in patients with myocarditis. Eur Heart J 2024 (Supplement abstract): prognostic multiparametric score including septal LGE, LGE persistence at 6-month CMR, troponin persistence, reduced LVEF, and impaired GLS.
Eichhorn C, et al. Multiparametric CMR to differentiate chronic from healed myocarditis; follow-up at ~3 months to identify high-risk LGE extent/patterns. JACC: Cardiovascular Imaging 2022.
Ammirati E, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: role of CMR and timing (2–3 weeks; follow-up). Circ Heart Fail 2020.
Berg J, et al. Enzymes/inflammatory markers may normalize despite persistent LGE on CMR. Circ Heart Fail 2017.
Popa A, et al. Integrating CMR with biomarkers improves risk stratification in acute myocarditis. Diagnostics 2024.
Tschöpe C, et al. Myocarditis and inflammatory cardiomyopathy: current concepts and evidence synthesis. Nat Rev Cardiol 2021.
Uccello G, et al. Chronic inflammatory cardiomyopathy and persistence of inflammation over time. Front Cardiovasc Med 2023.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.